EA201101304A1 - Новая кристаллическая форма vi агомелатина, ее получение и применение - Google Patents
Новая кристаллическая форма vi агомелатина, ее получение и применениеInfo
- Publication number
- EA201101304A1 EA201101304A1 EA201101304A EA201101304A EA201101304A1 EA 201101304 A1 EA201101304 A1 EA 201101304A1 EA 201101304 A EA201101304 A EA 201101304A EA 201101304 A EA201101304 A EA 201101304A EA 201101304 A1 EA201101304 A1 EA 201101304A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- agomelatin
- reception
- application
- crystal form
- crystalline form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Battery Electrode And Active Subsutance (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретение обеспечивает новую кристаллическую форму агомелатина, ее получение и применение. Диаграмма рентгеновской порошковой дифрактометрии кристаллической формы агомелатина показывает основные пики при углах дифракции 2θ 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° и 31.93°. Упомянутая новая кристаллическая форма отличается высокой чистотой, стабильностью и хорошей воспроизводимостью и поэтому является выгодной для фармацевтических препаратов. К тому же, стабильность и растворимость упомянутой кристаллической формы также выше, чем у некоторых существующих кристаллических форм.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910047329.2A CN101585779B (zh) | 2009-03-10 | 2009-03-10 | 阿戈美拉汀的晶型vi及其制备方法和应用 |
PCT/CN2010/070931 WO2010102554A1 (zh) | 2009-03-10 | 2010-03-09 | 阿戈美拉汀的新晶型ⅵ及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201101304A1 true EA201101304A1 (ru) | 2012-04-30 |
EA019127B1 EA019127B1 (ru) | 2014-01-30 |
Family
ID=41370233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201101304A EA019127B1 (ru) | 2009-03-10 | 2010-03-09 | Новая кристаллическая форма vi агомелатина, ее получение и применение |
Country Status (27)
Country | Link |
---|---|
US (1) | US8614251B2 (ru) |
EP (1) | EP2431355A4 (ru) |
JP (1) | JP2012519715A (ru) |
KR (1) | KR20110123266A (ru) |
CN (1) | CN101585779B (ru) |
AP (1) | AP3049A (ru) |
AU (1) | AU2010223720B2 (ru) |
BR (1) | BRPI1013249A2 (ru) |
CA (1) | CA2754276A1 (ru) |
CL (1) | CL2011002231A1 (ru) |
CO (1) | CO6410293A2 (ru) |
CR (1) | CR20110457A (ru) |
CU (1) | CU20110162A7 (ru) |
EA (1) | EA019127B1 (ru) |
EC (1) | ECSP11011309A (ru) |
GE (1) | GEP20146114B (ru) |
HN (1) | HN2011002408A (ru) |
IL (1) | IL214683A0 (ru) |
MA (1) | MA33100B1 (ru) |
MX (1) | MX2011009339A (ru) |
NI (1) | NI201100167A (ru) |
PE (1) | PE20120653A1 (ru) |
SG (2) | SG173692A1 (ru) |
TN (1) | TN2011000426A1 (ru) |
UA (1) | UA100476C2 (ru) |
WO (1) | WO2010102554A1 (ru) |
ZA (1) | ZA201106049B (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101585779B (zh) * | 2009-03-10 | 2014-04-02 | 上海医药工业研究院 | 阿戈美拉汀的晶型vi及其制备方法和应用 |
WO2011006387A1 (zh) * | 2009-07-11 | 2011-01-20 | 浙江华海药业股份有限公司 | 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法 |
CN101955440B (zh) * | 2009-07-17 | 2014-04-09 | 江苏万特制药有限公司 | 一种阿戈美拉汀新晶型及其制备方法 |
CN102050756A (zh) * | 2009-11-09 | 2011-05-11 | 北京利乐生制药科技有限公司 | 阿戈美拉汀新晶型及其制备方法 |
CN102190595A (zh) | 2010-03-17 | 2011-09-21 | 上海医药工业研究院 | 阿戈美拉汀溴化氢水合物及其制备方法 |
CN102557979B (zh) * | 2010-12-16 | 2014-11-26 | 北大方正集团有限公司 | 一种阿戈美拉汀的晶型、其制备方法、用途及药物组合物 |
WO2012093402A1 (en) * | 2011-01-04 | 2012-07-12 | Symed Labs Limited | Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide |
CN102690210A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物 |
CN102690209A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物 |
FR2978916B1 (fr) | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
WO2013082302A1 (en) | 2011-11-30 | 2013-06-06 | Ratiopharm Gmbh | Agomelatine-urea complex and crystalline forms thereof |
FR3001894A1 (fr) | 2013-02-08 | 2014-08-15 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
CN103690499B (zh) * | 2013-12-23 | 2015-05-06 | 天津泰普药品科技发展有限公司 | 一种稳定的晶i型阿戈美拉汀片剂及其制备方法 |
WO2015124496A1 (en) | 2014-02-19 | 2015-08-27 | Synthon B.V. | Pharmaceutical composition comprising amorphous agomelatine |
EP3075724B1 (en) | 2015-03-31 | 2023-07-12 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Solid form of agomelatine |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2866335B1 (fr) * | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
FR2866334B1 (fr) * | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine |
FR2889521B1 (fr) * | 2005-08-03 | 2007-12-28 | Servier Lab | Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
FR2889523B1 (fr) * | 2005-08-03 | 2007-12-28 | Servier Lab | Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
FR2889522B1 (fr) * | 2005-08-03 | 2007-12-28 | Servier Lab | Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
FR2899472B1 (fr) * | 2006-04-07 | 2008-09-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee |
FR2923482B1 (fr) * | 2007-11-09 | 2010-01-29 | Servier Lab | Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
CN101585779B (zh) * | 2009-03-10 | 2014-04-02 | 上海医药工业研究院 | 阿戈美拉汀的晶型vi及其制备方法和应用 |
EP2319827A1 (en) * | 2009-11-09 | 2011-05-11 | Ratiopharm GmbH | Process for the production of polymorph form I of agomelatine |
-
2009
- 2009-03-10 CN CN200910047329.2A patent/CN101585779B/zh not_active Expired - Fee Related
-
2010
- 2010-03-09 US US13/138,615 patent/US8614251B2/en not_active Expired - Fee Related
- 2010-03-09 WO PCT/CN2010/070931 patent/WO2010102554A1/zh active Application Filing
- 2010-03-09 CA CA2754276A patent/CA2754276A1/en not_active Abandoned
- 2010-03-09 AU AU2010223720A patent/AU2010223720B2/en not_active Ceased
- 2010-03-09 JP JP2011553265A patent/JP2012519715A/ja active Pending
- 2010-03-09 SG SG2011058559A patent/SG173692A1/en unknown
- 2010-03-09 AP AP2011005914A patent/AP3049A/xx active
- 2010-03-09 KR KR1020117021813A patent/KR20110123266A/ko not_active Application Discontinuation
- 2010-03-09 BR BRPI1013249A patent/BRPI1013249A2/pt not_active Application Discontinuation
- 2010-03-09 SG SG2011088564A patent/SG177886A1/en unknown
- 2010-03-09 PE PE2011001513A patent/PE20120653A1/es not_active Application Discontinuation
- 2010-03-09 EP EP10750350A patent/EP2431355A4/en not_active Withdrawn
- 2010-03-09 UA UAA201111757A patent/UA100476C2/ru unknown
- 2010-03-09 GE GEAP201012406A patent/GEP20146114B/en unknown
- 2010-03-09 EA EA201101304A patent/EA019127B1/ru not_active IP Right Cessation
- 2010-03-09 MA MA34144A patent/MA33100B1/fr unknown
- 2010-03-09 MX MX2011009339A patent/MX2011009339A/es not_active Application Discontinuation
-
2011
- 2011-08-16 IL IL214683A patent/IL214683A0/en unknown
- 2011-08-17 ZA ZA2011/06049A patent/ZA201106049B/en unknown
- 2011-08-17 TN TN2011000426A patent/TN2011000426A1/fr unknown
- 2011-08-23 CU CU20110162A patent/CU20110162A7/es unknown
- 2011-08-24 CR CR20110457A patent/CR20110457A/es unknown
- 2011-08-26 CO CO11109271A patent/CO6410293A2/es not_active Application Discontinuation
- 2011-09-07 EC EC2011011309A patent/ECSP11011309A/es unknown
- 2011-09-08 NI NI201100167A patent/NI201100167A/es unknown
- 2011-09-09 HN HN2011002408A patent/HN2011002408A/es unknown
- 2011-09-09 CL CL2011002231A patent/CL2011002231A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20110123266A (ko) | 2011-11-14 |
ECSP11011309A (es) | 2011-10-31 |
EP2431355A4 (en) | 2012-08-08 |
US8614251B2 (en) | 2013-12-24 |
WO2010102554A1 (zh) | 2010-09-16 |
HN2011002408A (es) | 2014-06-23 |
AU2010223720B2 (en) | 2012-05-03 |
EA019127B1 (ru) | 2014-01-30 |
CU20110162A7 (es) | 2012-02-15 |
US20120004313A1 (en) | 2012-01-05 |
CN101585779B (zh) | 2014-04-02 |
PE20120653A1 (es) | 2012-06-14 |
SG177886A1 (en) | 2012-02-28 |
MA33100B1 (fr) | 2012-03-01 |
AU2010223720A1 (en) | 2011-09-08 |
GEP20146114B (en) | 2014-07-10 |
SG173692A1 (en) | 2011-09-29 |
CO6410293A2 (es) | 2012-03-30 |
CR20110457A (es) | 2011-09-21 |
BRPI1013249A2 (pt) | 2016-04-05 |
JP2012519715A (ja) | 2012-08-30 |
CA2754276A1 (en) | 2010-09-16 |
TN2011000426A1 (en) | 2013-03-27 |
CN101585779A (zh) | 2009-11-25 |
NI201100167A (es) | 2012-01-11 |
AP3049A (en) | 2014-11-30 |
IL214683A0 (en) | 2011-11-30 |
EP2431355A1 (en) | 2012-03-21 |
MX2011009339A (es) | 2011-09-27 |
CL2011002231A1 (es) | 2012-02-03 |
UA100476C2 (en) | 2012-12-25 |
ZA201106049B (en) | 2012-10-31 |
AP2011005914A0 (en) | 2011-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201101304A1 (ru) | Новая кристаллическая форма vi агомелатина, ее получение и применение | |
EA200802119A1 (ru) | Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат | |
PH12015502825B1 (en) | Crystals | |
EA200601274A1 (ru) | Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
EA200601273A1 (ru) | Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
EA200601271A1 (ru) | Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
EA201101208A1 (ru) | Гидрогалогенидный комплекс агомелатина и его получение | |
EA201201294A1 (ru) | Гидрат гидрохлорида агомелатина и его получение | |
EA200801777A1 (ru) | α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ | |
HRP20230813T1 (hr) | Upadacitinib solni spoj i postupak njegove pripreme | |
MY143557A (en) | Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it | |
RU2019100065A (ru) | Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR | |
AR075418A1 (es) | Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad. | |
RU2015114085A (ru) | Кристаллические формы производных дигидропиримидина | |
RS53001B (en) | DELTA CRYSTAL FORM OF ARGININE SALT PERINDOPRIL, PROCEDURE FOR ITS MANUFACTURE AND PHARMACEUTICAL MIXTURES CONTAINING IT | |
EA200900936A1 (ru) | Аморфные и кристаллические формы ривастигмина гидротартрата | |
EA201290156A1 (ru) | Комплексы вилдаглиптина с неорганической солью | |
ATE479728T1 (de) | Neue kristallphase eines benzimidazolon-azo- pigments | |
WO2012044189A8 (en) | A new hydrated crystalline form of perindopril erbumine, methods for its preparation and its use in pharmaceutical preparations | |
TH120304A (th) | รูปแบบที่เป็นผลึก vi แบบใหม่ของอะโกเมลาทีน, การเตรียม และการใช้ของสิ่งนี้ | |
UA59402U (ru) | Кристаллический состав комбинированного лекарственного препарата анальгетического, противовоспалительного и жаропонижающего действия | |
TH120304B (th) | รูปแบบที่เป็นผลึก vi แบบใหม่ของอะโกเมลาทีน, การเตรียม และการใช้ของสิ่งนี้ | |
UA108849C2 (xx) | Кристалічна форма 2-{4-[n-(5,6-дифенілпіразин-2-іл)-n-ізопропіламіно]бутилокси}-n-(метилсульфоніл)ацетаміду |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |